CoChat

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

Open access
De Giorgi, Ugo, Procopio, Giuseppe, Giannarelli, Diana, Sabbatini, Roberto, Bearz, Alessandra, Buti, Sebastiano, Basso, Umberto, Mitterer, Manfred, Ortega, Cinzia, Bidoli, Paolo, Ferraù, Francesco, Crinò, Lucio, Frassoldati, Antonio, Marchetti, Paolo, Mini, Enrico, Scoppola, Alessandro, Verusio, Claudio, Fornarini, Giuseppe, Cartenì, Giacomo, Caserta, Claudia, Sternberg, Cora N. · 2019 · Clinical Cancer Research
Cited by 226

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Purpose: Inflammation indexes and body mass index (BMI) are easily evaluated, predict survival, and are potentially modifiable. We evaluated the potential association of inflammatory indexes and BMI with the clinical outcome of patients with renal cell carcinoma (RCC) undergoing immune checkpoint inhibitor therapy. Experimental Design: A prospective cohort of patients with metastatic RCC treated with nivolumab enrolled in the Italian Expanded Access Program from July 2015 through April 2016 was examined. Reference measures of inflammation were identified for neutrophil-to-lymphocyte ratio (NLR) </≥ 3, systemic immune inflammation index (SII) </≥ 1,375, and platelet-to-lymphocyte ratio (PLR) </≥ 232. Patients were classified as high BMI (≥25 kg/m2) versus normal BMI (<25 kg/m2). Results: Among 313 evaluable patients, 235 (75.1%) were male, and median age was 65 years (range, 40–84 years), with 105 (33.69%) ≥70 years. In univariate analysis, age, performance status, BMI, SII, NLR, and PLR were able to predict outcome. In multivariate analyses, SII ≥1,375, BMI <25 kg/m2, and age ≥70 years independently predicted overall survival [OS; HR = 2.96, 95% confidence interval (CI), 2.05–4.27; HR = 1.59, 95% CI, 1.10–2.30; and HR = 1.65, 95% CI, 1.07–2.55, respectively). A patient with both SII ≥1,375 and BMI <25 kg/m2 was estimated to have much worse OS (HR, 3.37; 95% CI, 2.29–4.95; P <0.0001) than a patient with neither or only one risk factor. SII changes at 3 months predicted OS (P <0.0001). Conclusions: Normal BMI combined with inflammation tripled the risk of death, suggesting that these biomarkers are critical prognostic factors for OS in patients with RCC treated with nivolumab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-3661

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 226

Metadata

Authors
De Giorgi, U., Procopio, G., Giannarelli, D., Sabbatini, R., Bearz, A., Buti, S., Basso, U., Mitterer, M., Ortega, C., Bidoli, P., Ferraù, F., Crinò, L., Frassoldati, A., Marchetti, P., Mini, E., Scoppola, A., Verusio, C., Fornarini, G., Cartenì, G., Caserta, C., & Sternberg, C. N.
Venue
Clinical Cancer Research
Published
2019-07-01
Volume
25
Issue
13
Pages
3839-3846
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2937003735
Cited by
226
References
8
FWCI
12.33
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-3661
The paper
De Giorgi, U., Procopio, G., Giannarelli, D., Sabbatini, R., Bearz, A., Buti, S., Basso, U., Mitterer, M., Ortega, C., Bidoli, P., Ferraù, F., Crinò, L., Frassoldati, A., Marchetti, P., Mini, E., Scoppola, A., Verusio, C., Fornarini, G., Cartenì, G., . . . Sternberg, C. N. (2019). Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-3661

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.